Home › Compare › IFABF vs ABBV
IFABF yields 87.53% · ABBV yields 3.06%● Live data
📍 IFABF pulled ahead of the other in Year 1
Combined, IFABF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IFABF + ABBV for your $10,000?
iFabric Corp. designs and distributes women's intimate apparel and accessories in Canada, the United States, the United Kingdom, Southeast Asia, and internationally. The company's Intimate Apparel division engages in the design, purchase, and distribution of intimate apparel, which includes a range of specialty bras, including reversible bra, patented bandeaux bra, and patented breast lift products. Its Intelligent Fabrics division engages in development, testing, and distribution of specialty textiles and chemicals for textiles, such as Protx2, an anti-microbial and anti-viral formulations; Enguard, an insect repellant technology; Dreamskin, a skin polymer; UVtx, an ultraviolet light blocker; FreshTx, an odor absorbing technology; RepelTX, a durable water repellant; Omega+, a joint and muscle recovery; TempTx, a thermal regulator; Apollo, a body odor neutralizer; DryTx, a moisture-wicking technology; BioTX, a metal free anti-stink solution; RepelTX Eco Plus, a fluorine-free durable water repellant; IMPRINT, a logo exposing moisture-wicker; and DriForce, a fabric interior moisture wicker. iFabric Corp. was founded in 1985 and is headquartered in Markham, Canada.
Full IFABF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.